Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of HS-20094 injection in adults with overweight or obesity
CTR20243973Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing HS-20094 with Placebo (2 arms). Started Oct 2024; status: completed.
02
Drugs
olatorepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20243973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243973.